Balyasny Asset Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$4.42M Sell
155,010
-702,595
-82% -$18.7M 0.01% 1487
2026
Q2
$20.7M Sell
857,605
-9,613,783
-92% -$251M 0.03% 703
2026
Q1
$294M Buy
10,471,388
+1,926,496
+23% +$51.3M 0.38% 34
2025
Q4
$213M Buy
8,544,892
+4,026,322
+89% +$102M 0.27% 63
2025
Q3
$115M Buy
4,518,570
+1,422,123
+46% +$35.1M 0.15% 139
2025
Q2
$75.1M Buy
3,096,447
+2,592,289
+514% +$60.5M 0.11% 216
2025
Q1
$12.8M Sell
504,158
-3,286,772
-87% -$86M 0.02% 786
2024
Q4
$101M Buy
3,790,930
+2,479,836
+189% +$67.3M 0.15% 150
2024
Q3
$37.9M Sell
1,311,094
-5,133,175
-80% -$150M 0.06% 400
2024
Q2
$180M Buy
6,444,269
+5,800,893
+902% +$160M 0.32% 46
2024
Q1
$17.9M Sell
643,376
-1,726,673
-73% -$47.9M 0.03% 662
2023
Q4
$68.2M Sell
2,370,049
-5,222,829
-69% -$158M 0.13% 194
2023
Q3
$252M Buy
7,592,878
+7,107,540
+1,464% +$251M 0.51% 20
2023
Q2
$17.8M Buy
485,338
+296,988
+158% +$11.6M 0.04% 572
2023
Q1
$7.68M Sell
188,350
-42,557
-18% -$1.84M 0.02% 887
2022
Q4
$11.8M Buy
230,907
+135,029
+141% +$6.47M 0.03% 676
2022
Q3
$4.2M Buy
95,878
+66,750
+229% +$3.24M 0.01% 1093
2022
Q2
$1.53M Sell
29,128
-8,905
-23% -$454K 0.01% 1552
2022
Q1
$1.97M Sell
38,033
-1,168,797
-97% -$60.6M 0.01% 1362
2021
Q4
$71.3M Buy
1,206,830
+1,067,959
+769% +$52.9M 0.24% 76
2021
Q3
$5.97M Buy
+138,871
New +$6.15M 0.02% 761
2020
Q4
– Sell
-1,474,423
Closed -$54.1M – 1604
2020
Q3
$54.1M Buy
1,474,423
+283,664
+24% +$10.5M 0.4% 45
2020
Q2
$38.9M Sell
1,190,759
-293,400
-20% -$10.5M 0.34% 62
2020
Q1
$48.4M Buy
+1,484,159
New +$53.3M 0.57% 25
2019
Q3
– Sell
-5,736
Closed -$248K – 1484
2019
Q2
$248K Sell
5,736
-2,073,189
-100% -$86.8M ﹤0.01% 1368
2019
Q1
$88.3M Buy
2,078,925
+2,073,124
+35,737% +$87.5M 0.59% 16
2018
Q4
$253K Sell
5,801
-427,606
-99% -$18.7M ﹤0.01% 1263
2018
Q3
$19.1M Buy
433,407
+359,909
+490% +$14.6M 0.09% 312
2018
Q2
$2.67M Sell
73,498
-52,260
-42% -$1.88M 0.01% 842
2018
Q1
$4.46M Sell
125,758
-193,216
-61% -$7M 0.02% 744
2017
Q4
$11.6M Buy
318,974
+218,974
+219% +$7.87M 0.04% 588
2017
Q3
$3.57M Buy
100,000
+71,000
+245% +$2.41M 0.01% 817
2017
Q2
$974K Sell
29,000
-379,556
-93% -$12.6M ﹤0.01% 1112
2017
Q1
$14M Buy
408,556
+322,141
+373% +$10.7M 0.07% 381
2016
Q4
$2.81M Sell
86,415
-374,646
-81% -$12.1M 0.02% 825
2016
Q3
$15.6M Sell
461,061
-190,791
-29% -$6.72M 0.09% 300
2016
Q2
$23M Buy
651,852
+163,057
+33% +$5.49M 0.15% 178
2016
Q1
$14.5M Buy
488,795
+481,035
+6,199% +$14.5M 0.09% 309
2015
Q4
$250K Sell
7,760
-3,248,944
-100% -$108M ﹤0.01% 1026
2015
Q3
$102M Buy
3,256,704
+2,238,618
+220% +$75.7M 0.76% 14
2015
Q2
$34.1M Sell
1,018,086
-719,535
-41% -$24.7M 0.21% 119
2015
Q1
$60.5M Buy
1,737,621
+593,503
+52% +$19.9M 0.49% 36
2014
Q4
$35.6M Buy
+1,144,118
New +$34.6M 0.33% 79

Other funds holding PFE

Balyasny Asset Management's PFE Position: Q3 2026 in Review

Balyasny Asset Management reduced its Pfizer (PFE) stake by 82% in Q3 2026, selling an estimated $18.7M and leaving 155,010 shares worth $4.42M. The position accounts for 0.01% of the portfolio, ranked #1487.

Balyasny Asset Management first reported a position in PFE in Q4 2014 and has held it in 43 quarters since. The position peaked at $294M in Q1 2026. 2,918 funds tracked by Wall St. Rank hold PFE as of Q3 2026.

  • Balyasny Asset Management held 155,010 shares of Pfizer worth $4.42M as of Q3 2026.
  • Balyasny Asset Management sold 702,595 Pfizer shares in Q3 2026, an estimated $18.7M.
  • Pfizer made up 0.01% of Balyasny Asset Management's portfolio in Q3 2026, its #1487 holding.
  • Balyasny Asset Management first reported a position in Pfizer in Q4 2014 and has held it in 43 quarters since.
  • Balyasny Asset Management's Pfizer position peaked at $294M in Q1 2026.
  • 2,918 funds tracked by Wall St. Rank held Pfizer as of Q3 2026.

Based on Balyasny Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.